Education
About Us
Working with TipRanks
Follow Us
Evaxion Biotech (EVAX)
NASDAQ:EVAX
Earnings Data
Report Date
Jun 02, 2026Before Open (Not Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.01Last Year’s EPS
-0.01Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized substantial scientific and operational progress: strong Phase II EVX-01 results with high response and immunogenicity rates, multiple platform innovations (including an automated design module), notable partnerships and external recognition, and improved financing that extends runway into H2 2027. Headwinds include a continued net loss, remaining dilution risk from warrants/ADS conversion, the need to further validate programs to convert partner interest into transactions, and that several programs are still preclinical/early clinical. Overall, positives around clinical validation, platform advances, partnerships and cash runway materially outweigh the operational and commercialization risks at this stage.Company Guidance
Strong EVX-01 Clinical Results (Phase II, Advanced Melanoma)
Objective response rate of 75% and complete response rate of 25% at 2 years; 92% of responders remained in response at the 2-year mark. High immunogenicity: 81% of individual neoantigens administered elicited a specific T-cell response, positioning the platform above comparable programs (others reported hit rates <60%). Additional biomarker/immunogenicity updates expected H1 2026 and 3-year data in H2 2026.
MSD Collaboration and First AI-Discovered Infectious Disease Licensing
Merck (MSD) exercised its option on EVX-B3, noted as the first known in-licensing of an infectious disease vaccine candidate identified/validated by an AI discovery platform — validating commercial interest in Evaxion's AI immunology technology.
EVX-04 Preclinical Success (AML)
EVX-04 vaccine designed to 16 optimal endogenous retroviral (ERV) fragments induced strong, specific T-cell responses and prevented tumor growth in multiple preclinical models. Planned clinical trial application submission in H2 2026 (first-in-human milestone).
EVX-B2 Gonorrhea Preclinical Package (Retained Global Rights)
Comprehensive preclinical data showing significant protection in mouse infection models, broad efficacy across ~50 clinically relevant strains, potent antibody-dependent complement-mediated killing, and both humoral and cellular responses — positioning EVX-B2 as a differentiated preclinical gonorrhea candidate in an area of high unmet need.
EVX-B1 CMV Multi-Antigen Strategy and Antigen Engineering
CMV program integrates engineered known glycoproteins and novel antigens; an AI-designed prefusion-locked glycoprotein B construct demonstrated superior neutralization capacity versus native form, aiming to reduce viral escape risk via a multicomponent approach.
Platform Innovation: Automated Vaccine Design Module Launched
In October 2025 Evaxion launched an automated vaccine design module that integrates multiomic data and generates ranked antigen lists within 24 hours, reducing cost and development time while improving antigen construct expression, formulation and manufacturability — strengthening end-to-end discovery-to-design workflow.
Strategic Partnerships and Recognition
Entered collaboration with the Gates Foundation on polio vaccine design; received recognition from the Galien Foundation for AI advances in human health — bolstering scientific credibility and external validation of the platform.
Improved Financial Position and Extended Cash Runway
2025 cash inflows totaled approximately USD 32 million from financing, ATM activity and MSD option fees. EIB debt-to-equity conversion reported (USD 4.1 quoted in transcript), net loss improved to USD 7.7 million for the year, and year-end cash position of USD 23 million provides runway into H2 2027. Outstanding ADS convertible basis ~8.3 million; warrant exercises reduced potential dilution by ~1.0 million ADS equivalents.
EVAX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
EVAX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 05, 2026 | $3.11 | $3.40 | +9.32% |
Nov 06, 2025 | $5.66 | $6.26 | +10.60% |
Aug 14, 2025 | $3.04 | $2.86 | -5.92% |
May 27, 2025 | $1.88 | $2.36 | +25.53% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Evaxion Biotech (EVAX) report earnings?
Evaxion Biotech (EVAX) is schdueled to report earning on Jun 02, 2026, Before Open (Not Confirmed).
What is Evaxion Biotech (EVAX) earnings time?
Evaxion Biotech (EVAX) earnings time is at Jun 02, 2026, Before Open (Not Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EVAX EPS forecast?
EVAX EPS forecast for the fiscal quarter 2026 (Q1) is -0.01.